# Astral Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astral-systems

- Industry: Power & Utilities
- Headquarters: Bristol, UK
- Website: www.astralsystems.com
- Total disclosed funding: $30M
- Latest round: Series A (Mar 27, 2026)
- Investors on record: 7

## About

Based in Bristol, England, Astral Systems operates as a nuclear technology company developing compact fusion reactors and neutron source systems. The company focuses on providing neutron irradiation services, medical isotope production solutions, and advanced fusion-based technologies for healthcare, energy, and industrial applications.Based in Bristol, England and founded in 2021, Astral Neutronics Ltd. (trading as Astral Systems) was founded by Talmon Firestone and provides compact fusion reactor technology, neutron generation systems, neutron irradiation services, and medical isotope production solutions for the nuclear technology and healthcare sectors. The company commercializes its proprietary Multi-State Fusion (MSF) technology to enable decentralized neutron and isotope production.In June 2026, Astral Systems raised GBP 23 million in series A funding led by Mercia Asset Management, with participation from Blast.Club, Daphni, and Tees River, Playfair Capital, Speedinvest, Angel Investors Bristol and other unspecified investors also participated in the round.Astral Systems focuses on the development and deployment of next-generation fusion technology, specifically through its innovative multi-state fusion reactors. These reactors utilize lattice confinement fusion (LCF) technology to achieve solid-state fuel densities significantly higher than traditional plasma methods, offering high particle flux and exceptional lifetime performance. The primary applications of these reactors extend across medical, industrial, and research sectors, including the production of medical isotopes for diagnostic and therapeutic purposes. By situating their reactors near healthcare facilities, Astral Systems aims to enhance medical access while reducing costs and wait times. The company primarily serves clients in North America, Europe, and select markets in Asia, collaborating with hospitals, research institutions, and industrial partners to facilitate advancements in nuclear medicine and carbon-free energy solutions.The company generates revenue through the sale of fusion reactor systems and neutron-generation equipment. Additional revenue is derived from neutron irradiation services, medical isotope production, research collaborations, and commercial licensing of its fusion technology.

## Funding rounds

- Series A, Mar 27, 2026, $30M — Mercia Asset Management, Speedinvest, Daphni, Playfair Capital, Blast.Club, Angel Investors Bristol, Tees River

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Series A
- Speedinvest (https://capitalatlas.ai/funds/speedinvest) — Series A
- Daphni (https://capitalatlas.ai/funds/daphni) — Series A
- Playfair Capital (https://capitalatlas.ai/funds/playfair-capital) — Series A
- Blast.Club (https://capitalatlas.ai/funds/blast-club) — Series A
- Angel Investors Bristol — Series A
- Tees River — Series A